Managing Immune Checkpoint-Blocking Antibody Side Effects
Immune checkpoint-blocking antibodies that enhance the immune system's ability to fight cancer are becoming important components of treatment for patients with a variety of malignancies. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) was the first immune checkpoint to be clinically target...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Revisão |
| Jazyk: | angličtina |
| Vydáno: |
2015
|
| On-line přístup: | https://doi.org/10.14694/edbook_am.2015.35.76 https://ascopubs.org/doi/pdfdirect/10.14694/EdBook_AM.2015.35.76 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|